Heart:动态血压和房颤长期风险!

2018-02-10 xing.T MedSci原创

由此可见,在基于人群的队列中,收缩期ABP是发生AF的重要预测因子。研究人员还观察到白天收缩压负荷>38%的参与者发生AF的风险显著增加。

关于动态血压(ABP)组分对房颤(AF)发生风险贡献的数据十分有限。近日,在心脏病领域权威杂志Heart上发表了一篇研究文章,研究人员旨在前瞻性地检验这样一个假设,即在欧洲人群研究中,ABP可能是房颤发生发展的潜在危险因素。

研究人员记录了5个欧洲国家随机从普通人群中招募的3956名受试者白天血压(BP)。其中2776例(70.2%)参与者接受了完整的24小时ABP监测。中位随访时间为14年。研究人员将白天收缩压负荷定义为BP读数高于135mmHg的百分比。根据基线和随访时获得的心电图以及全科医生和/或医院的病历记录评估房颤的发生率。

总的来说,在58810人次每年的随访中,143名参与者发生了新发房颤。在校正后的Cox模型中,基线24h、白天和夜间收缩压水平每增加1个标准差发生AF的风险增加分别为27%(P=0.0056)、22%(P=0.023)和20%(P=0.029)。常规收缩压与房颤发生风险有关(18%; P=0.06)。与平均人群危险度相比,日间收缩压负荷位于最低四分位(<3%)参与者发生AF的风险降低了51%(P=0.0038),而最高四分位数(>38%),风险增加了46%(P=0.0094)。

由此可见,在基于人群的队列中,收缩期ABP是发生AF的重要预测因子。研究人员还观察到白天收缩压负荷>38%的参与者发生AF的风险显著增加。

原始出处:

Valérie Tikhonoff,et al. Ambulatory blood pressure and long-term risk for atrial fibrillation. Heart. 2018. http://dx.doi.org/10.1136/heartjnl-2017-312488

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1356678, encodeId=54a513566e8a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401335, encodeId=9d1b140133589, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509000, encodeId=8fd4150900066, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562823, encodeId=6e0c156282313, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286817, encodeId=e36c28681ec2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Feb 10 14:55:21 CST 2018, time=2018-02-10, status=1, ipAttribution=)]
    2018-02-12 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1356678, encodeId=54a513566e8a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401335, encodeId=9d1b140133589, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509000, encodeId=8fd4150900066, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562823, encodeId=6e0c156282313, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286817, encodeId=e36c28681ec2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Feb 10 14:55:21 CST 2018, time=2018-02-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1356678, encodeId=54a513566e8a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401335, encodeId=9d1b140133589, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509000, encodeId=8fd4150900066, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562823, encodeId=6e0c156282313, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286817, encodeId=e36c28681ec2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Feb 10 14:55:21 CST 2018, time=2018-02-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1356678, encodeId=54a513566e8a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401335, encodeId=9d1b140133589, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509000, encodeId=8fd4150900066, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562823, encodeId=6e0c156282313, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286817, encodeId=e36c28681ec2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Feb 10 14:55:21 CST 2018, time=2018-02-10, status=1, ipAttribution=)]
    2018-02-12 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1356678, encodeId=54a513566e8a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401335, encodeId=9d1b140133589, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509000, encodeId=8fd4150900066, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562823, encodeId=6e0c156282313, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 12 04:59:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286817, encodeId=e36c28681ec2, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Feb 10 14:55:21 CST 2018, time=2018-02-10, status=1, ipAttribution=)]
    2018-02-10 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0

相关资讯

Heart:肾脏去神经降压幅度与试验设计相关

英国一项研究表明,在实施双盲安慰剂对照的药物试验中,诊室和动态血压降低差异趋向于消失;肾脏去神经试验亦有可能随试验设计改进而出现类似表现。论文9月15日在线发表于《心脏》(Heart)。 肾脏去神经试验报告诊室收缩压降低30 mmHg,但动态血压降低远逊于此。上述差异可能具有生理学偏倚,并且在降压药物试验中亦可能出现。此项研究通过药物和肾脏去神经试验荟萃分析评估了诊室-动态血压

Eur Heart J:诊所血压或动态血压能预测心血管风险吗?

2017年发表在《Eur Heart J》的一项由丹麦科学家进行的研究,考察了诊所血压或动态血压预测心血管事件的准确性。

ASH 2014:动态血压的心血管风险预测价值优于诊室/家庭血压

一项最新研究旨在比较诊室血压、家庭血压及动态血压对心血管风险的预测价值。 研究者芬兰国家卫生与福利研究所的Teemu Niiranen等入选464例受试者,测量其诊室血压、家庭血压、24小时动态血压及其他心血管危险因素。研究主要终点是心血管死亡、非致死性心肌梗死、非致死性卒中、因心力衰竭住院、行经皮冠状动脉介入治疗或冠状动脉旁路移植术等心血管事件的复合终点。采用Cox比例风险模型

Circulation:动态血压相关性风险呈年龄依赖性

亚欧一项研究表明,24小时动态舒张压(DBP24)和收缩压(SBP24)所致的风险具有年龄依赖性;年龄小于50岁时DBP24引发冠脉并发症,大于50岁时SBP24、单纯收缩压和混合型高血压则为主要危险因素。论文于6月6日在线发表于《循环》(Circulation)。 此项研究共随机纳入8341例未经治疗的受试者,并记录了24小时动态血压和健康转归。受试者平均年龄为50.8岁,女性为46.6%。利

Hypertension:动态血压再评估可改善慢性肾病患者肾脏危险分层

在未透析的慢性肾病患者中,动态血压(ABP)可更好地预测患者预后,但ABP的再评估是否能进一步改善预后尚不明确。近期的一项研究回答了上述问题,该研究表明,在未透析的慢性肾病患者中,1年时的ABP再评估可进一步改善肾脏预后;尤其是对那些基线时血压未得到控制的患者应考虑ABP的再评估。相关论文7月6日在线发表于《高血压》(HYPERTENSION)杂志。 该研究入组了182例未透析的慢性肾病高血压连